China’s Dizal Pharmaceutical has presented promising Phase I/II data for its fourth‑generation EGFR tyrosine kinase inhibitor (TKI), DZD6008. The company highlighted the candidate’s activity in patients with non‑small cell lung cancer (NSCLC) who had developed resistance to third‑generation EGFR TKIs, primarily due to C797X mutations. DZD6008 induced tumour shrinkage in 82.1% of evaluable patients, showed a 6‑month progression-free survival (PFS) rate of 70.6% at 40 mg, and demonstrated encouraging intracranial activity in patients with brain metastases.

The company also presented updated data on its JAK1 inhibitor, golidocitinib, in combination with an anti‑PD‑1 antibody for first‑line treatment of driver‑negative NSCLC. The combination showed durable anti‑tumour efficacy, particularly in patients with high PD‑L1 expression, and was associated with a manageable safety profile.

Dizal is advancing DZD6008 in global clinical development to address the significant unmet need in patients with resistance to standard EGFR therapies.

PharmCube's NextBiopharm® database lists over 50 EGFR TKI projects under active development poised to compete with the 5 products on the market. Click here to request a free trial for NextBiopharm®.